A study led by UCL found that individuals with rare diseases were five times more likely to die from Covid-19 than the ...

SE (NASDAQ:ARGX – Get Free Report) has earned an average rating of “Moderate Buy” from the twenty-two ratings firms that are presently covering the firm, Marketbeat.com reports. One investment analyst ...

A 58-year-old male patient presented to the dermatology clinic at West China Hospital of Sichuan University (Chengdu, Sichuan ...

Choreo LLC lifted its holdings in argenx SE (NASDAQ:ARGX – Free Report) by 4.4% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange ...

First up is the ADEPT study in bullous pemphigoid (BP), a rare skin condition ... with no relapse, and standard treatment with oral corticosteroids had been tailed off without the need for any ...

EYLEA HD is anticipated to gain traction with the launch of a prefilled syringe in mid-2025 and label expansions for macular edema and extended dosing intervals. Management believes these developments ...

An England-wide study of 331 rare diseases in over 58 million people co-led by UCL researchers has identified eight rare ...

An sBLA for Dupixent in bullous pemphigoid was submitted to the FDA ... The EC also approved Kevzara (sarilumab) for the treatment of polymyalgia rheumatica (PMR) and polyarticular juvenile ...

Finally, a supplementary BLA was submitted for bullous pemphigoid late last year ... total and food specific IgE levels following initial treatments at low doses. This trial is continuing to ...

Sanofi in partnership with Regeneron to present 24 abstracts across approved and investigational medicines at AAAAI Annual Meeting in San Diego: Paris Friday, February 7, 2025, 12 ...

The EU regulator is reviewing tralokinumab for the treatment of adult patients ... in chronic obstructive pulmonary disease (COPD), bullous pemphigoid, prurigo nodularis, chronic hives, and ...